Which Institutions Own Shares In Catalyst Pharmaceuticals Inc (CPRX)?

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is -20.46% lower on its value in year-to-date trading and has touched a low of $11.09 and a high of $18.22 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CPRX stock was last observed hovering at around $13.35 in the last trading session, with the day’s gains setting it 0.02%.

Currently trading at $13.37, the stock is -7.20% and -9.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.98 million and changing 0.15% at the moment leaves the stock -2.33% off its SMA200. CPRX registered -17.52% loss for a year compared to 6-month gain of -5.31%. The firm has a 50-day simple moving average (SMA 50) of $4.17 and a 200-day simple moving average (SMA200) of $14.51.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -12.56% loss in the last 1 month and extending the period to 3 months gives it a 4.05%, and is -7.35% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.59% over the week and 3.39% over the month.

Catalyst Pharmaceuticals Inc (CPRX) has around 82 employees, a market worth around $1.44B and $348.39M in sales. Current P/E ratio is 25.36 and Fwd P/E is 11.12. Profit margin for the company is 17.81%. Distance from 52-week low is 20.56% and -26.62% from its 52-week high. The company has generated returns on investments over the last 12 months (17.63%).

Catalyst Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at $0.26 with sales reaching $106.12M over the same period.The EPS is expected to shrink by -28.27% this year, but quarterly earnings will post 83.80% year-over-year. Quarterly sales are estimated to grow 74.70% in year-over-year returns.

354 institutions hold shares in Catalyst Pharmaceuticals Inc (CPRX), with institutional investors hold 75.81% of the company’s shares. The shares outstanding are 105.26M, and float is at 91.78M with Short Float at 6.49%. Institutions hold 71.10% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 15.85 million shares valued at $213.05 million. The investor’s holdings represent 14.87% of the CPRX Shares outstanding. As of Jun 29, 2023, the second largest holder is State Street Corporation with 9.45 million shares valued at $127.05 million to account for 8.87% of the shares outstanding. The other top investors are Deerfield Management Company, L.P. (Series C) which holds 8.19 million shares representing 7.69% and valued at over $110.1 million, while Vanguard Group Inc holds 6.45% of the shares totaling 6.87 million with a market value of $92.36 million.

Catalyst Pharmaceuticals Inc (CPRX) Insider Activity

A total of 0 insider transactions have happened at Catalyst Pharmaceuticals Inc (CPRX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Harper Molly, the company’s Director. SEC filings show that Harper Molly sold 14,000 shares of the company’s common stock on Dec 15 at a price of $14.39 per share for a total of $0.2 million. Following the sale, the insider now owns 0.0 shares.

Catalyst Pharmaceuticals Inc disclosed in a document filed with the SEC on Dec 12 that Tierney David S (Director) sold a total of 50,000 shares of the company’s common stock. The trade occurred on Dec 12 and was made at $13.32 per share for $0.67 million. Following the transaction, the insider now directly holds 0.33 million shares of the CPRX stock.

Still, SEC filings show that on Dec 11, GRANDE ALICIA (VP, Treasurer and CFO) disposed off 60,000 shares at an average price of $13.76 for $0.83 million. The insider now directly holds 50,557 shares of Catalyst Pharmaceuticals Inc (CPRX).

Catalyst Pharmaceuticals Inc (CPRX): Who are the competitors?

One of the company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -3.55% down over the past 12 months.Pfizer Inc. (PFE) lies in the list of competitors of the Catalyst Pharmaceuticals Inc and is -37.17% lower over the same period from CPRXAbbott Laboratories (ABT) is 3.95% up on the 1-year trading charts.